Capital International, Inc. Bei Gene, Ltd. Transaction History

Capital International, Inc.

$9.72 Billion
Q2 2025

A detailed history of Capital International, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital International, Inc. holds 345,559 shares of BGNE stock, worth $78.3 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares

345,559

Previous 437,382 20.99%

Holding current value

$78.3 Million

Previous $99.2 Million 20.99%

% of portfolio

0.81%

Previous 1.27%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	N/A	-91,823 Reduced 20.99%	345,559 $78.3 Million
Q1 2025 May 12, 2025	SELL	$175.1 - $226.71 $20.6 Million - $26.6 Million	-117,544 Reduced 21.18%	437,382 $99.2 Million
Q4 2024 Feb 13, 2025	SELL	$174.72 - $246.04 $12.2 Million - $17.2 Million	-69,969 Reduced 11.2%	554,926 $103 Million
Q3 2024 Nov 13, 2024	SELL	$143.93 - $224.51 $33.1 Million - $51.7 Million	-230,239 Reduced 26.92%	624,895 $140 Million
Q2 2024 Aug 13, 2024	SELL	$129.52 - $174.32 $418,349 - $563,053	-3,230 Reduced 0.38%	855,134 $122 Million
Q1 2024 May 14, 2024	BUY	$141.8 - $181.47 $6.89 Million - $8.82 Million	48,615 Added 6.0%	858,364 $134 Million
Q4 2023 Feb 13, 2024	SELL	$158.67 - $201.58 $6.26 Million - $7.96 Million	-39,482 Reduced 4.65%	809,749 $146 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $12.6 Million - $15.8 Million	-70,205 Reduced 7.64%	849,231 $153 Million
Q2 2023 Aug 11, 2023	SELL	$178.3 - $266.78 $13.8 Million - $20.7 Million	-77,606 Reduced 7.78%	919,436 $164 Million
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $21.7 Million - $27.7 Million	-100,857 Reduced 9.19%	997,042 $215 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $3.8 Million - $6.95 Million	-30,290 Reduced 2.68%	1,097,899 $241 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $1.98 Million - $3.04 Million	-15,016 Reduced 1.31%	1,128,189 $152 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $271,891 - $485,032	2,245 Added 0.2%	1,143,205 $185 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $20.7 Million - $38 Million	141,133 Added 14.12%	1,140,960 $215 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $3.06 Million - $4.79 Million	-12,308 Reduced 1.22%	999,827 $271 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $18.5 Million - $29.9 Million	74,276 Added 7.92%	1,012,135 $367 Million
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $28.7 Million - $36 Million	-98,071 Reduced 9.47%	937,859 $322 Million
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $11.4 Million - $16.8 Million	43,920 Added 4.43%	1,035,930 $361 Million
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $23.5 Million - $33.7 Million	-106,344 Reduced 9.68%	992,010 $256 Million
Q3 2020 Nov 13, 2020	SELL	$189.18 - $286.44 $2.91 Million - $4.41 Million	-15,388 Reduced 1.38%	1,098,354 $315 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $9.47 Million - $14.9 Million	76,470 Added 7.37%	1,113,742 $210 Million
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $9.32 Million - $13.3 Million	76,509 Added 7.96%	1,037,272 $128 Million
Q4 2019 Feb 18, 2020	SELL	$115.78 - $208.34 $753,843 - $1.36 Million	-6,511 Reduced 0.67%	960,763 $159 Million
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $75 Million - $92.3 Million	622,156 Added 180.27%	967,274 $118 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $3.66 Million - $4.72 Million	32,128 Added 10.26%	345,118 $42.8 Million
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $14.4 Million - $17.8 Million	117,318 Added 59.96%	312,990 $41.3 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $20.9 Million - $34.3 Million	195,672 New	195,672 $27.4 Million

Others Institutions Holding BGNE

# of Institutions

268

Shares Held

32.2M

Call Options Held

113K

Put Options Held

106K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.

Account

Capital International, Inc. Bei Gene, Ltd. Transaction History